Breaking News

Genzyme Acquires Campath from Bayer

Genzyme Corp. has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme Corp. has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath/MabCampath (alemtuzumab). Genzyme is now responsible for the development and commercialization of the drug and is conducting two Phase III studies of alemtuzumab in relapsing-remitting multiple sclerosis (MS) patients. Genzyme has also acquired the worldwide marketing and distribution rights to oncology drugs Fludara (fludarabine phosphate) and Leukine (sargramostim). Genzyme now has f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters